Indapta Therapeutics

Indapta Therapeutics company information, Employees & Contact Information

Updated May 2026

Quick answer

Indapta Therapeutics is a Biotechnology company. It has approximately 22 employees on record. Contact data was last refreshed in May 2026. Find Indapta Therapeutics's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Explore related pages

Indapta Therapeutics email format Indapta Therapeutics management contacts

Related company profiles:

Indapta's allogeneic g-NK cells have highly potent ADCC activity, making them the ideal therapy to combine with IgG1 monoclonal antibodies, ADCs, or innate immune cell engager molecules.

Company Details

Employees
22
Address
Seattle & Houston , Us
Industry
Biotechnology
Website
https://indapta.com/
Keywords
in multiple myeloma and drug development. We are encouraged that Sanofi appreciated the differentiated profile of IDP-023.
HQ
Seattle & Houston
Competitors
Outpace Bio, Akamis Bio, Citryll, Tune Therapeutics, Andelyn Biosciences, Atara Biotherapeutics, Shinobi Therapeutics, Tr1X, Umoja Biopharma, Sangamo Therapeutics, Inc..
Looking for a particular Indapta Therapeutics employee's phone or email?

Indapta Therapeutics Questions

News

UH Tech Bridge Community Member Indapta Therapeutics Advances Clinical Trials with $22.5M Funding - University of Houston

UH Tech Bridge Community Member Indapta Therapeutics Advances Clinical Trials with $22.5M Funding University of Houston

Indapta Therapeutics Secures $22.5 Million to Advance Clinical Trials of Innovative Cancer and Autoimmune Treatments - Business Wire

Indapta Therapeutics Secures $22.5 Million to Advance Clinical Trials of Innovative Cancer and Autoimmune Treatments Business Wire

Indapta Therapeutics Announces Clinical Study Collaboration With Sanofi on Multiple Myeloma Program - Business Wire

Indapta Therapeutics Announces Clinical Study Collaboration With Sanofi on Multiple Myeloma Program Business Wire

FDA Clears Indapta Therapeutics’ IND for Cell Therapy IDP-023 in Progressive Multiple Sclerosis - NeurologyLive

FDA Clears Indapta Therapeutics’ IND for Cell Therapy IDP-023 in Progressive Multiple Sclerosis NeurologyLive

SITC 2024 preview – late-breakers for Marengo and Indapta | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

SITC 2024 preview – late-breakers for Marengo and Indapta | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

FDA Fast Tracks IDP-023 for Non-Hodgkin Lymphoma and Myeloma - Targeted Oncology

FDA Fast Tracks IDP-023 for Non-Hodgkin Lymphoma and Myeloma Targeted Oncology

Indapta Therapeutics lands $22.5 million for cancer-fighting clinical trials - The Business Journals

Indapta Therapeutics lands $22.5 million for cancer-fighting clinical trials The Business Journals

Indapta Therapeutics Presents Clinical and Preclinical Data of Allogenic Natural Killer Cell Therapy at Society for Immunotherapy of Cancer Meeting - Business Wire

Indapta Therapeutics Presents Clinical and Preclinical Data of Allogenic Natural Killer Cell Therapy at Society for Immunotherapy of Cancer Meeting Business Wire

Indapta snags $50M financing and signs on former Juno exec as CEO - Fierce Biotech

Indapta snags $50M financing and signs on former Juno exec as CEO Fierce Biotech

Indapta Therapeutics Announces FDA Clearance of IND for Phase 1 Trial of IDP-023 for Progressive Multiple Sclerosis - Business Wire

Indapta Therapeutics Announces FDA Clearance of IND for Phase 1 Trial of IDP-023 for Progressive Multiple Sclerosis Business Wire

Indapta Therapeutics Names Mark W. Frohlich, M.D., Chief Executive Officer and Raises Over $50 Million in Series A Financing and Commitments to Advance Development of G-NK Cell Therapy to Treat Multiple Types of Cancer - Business Wire

Indapta Therapeutics Names Mark W. Frohlich, M.D., Chief Executive Officer and Raises Over $50 Million in Series A Financing and Commitments to Advance Development of G-NK Cell Therapy to Treat Multiple Types of Cancer Business Wire

Companies like Indapta Therapeutics

Shinobi Therapeutics logo - Similar company to Indapta Therapeutics

Shinobi Therapeutics

37
Andelyn Biosciences logo - Similar company to Indapta Therapeutics

Andelyn Biosciences

270
Akamis Bio logo - Similar company to Indapta Therapeutics

Akamis Bio

37
Sangamo Therapeutics, Inc. logo - Similar company to Indapta Therapeutics

Sangamo Therapeutics...

267
Tr1X logo - Similar company to Indapta Therapeutics

Tr1X

39
Outpace Bio logo - Similar company to Indapta Therapeutics

Outpace Bio

70
Umoja Biopharma logo - Similar company to Indapta Therapeutics

Umoja Biopharma

201
Atara Biotherapeutics logo - Similar company to Indapta Therapeutics

Atara Biotherapeutics

171
Tune Therapeutics logo - Similar company to Indapta Therapeutics

Tune Therapeutics

80
Citryll logo - Similar company to Indapta Therapeutics

Citryll

32

Top Indapta Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant